Inhibition of cellular contractility with ML-7 induces early membrane blebbing. Exponentially growing HUVECs were pretreated with vehicle (0.25% DMSO, 60 min; A and B) or with MLCK inhibitor ML-7 (25 μM, 60 min; C and D) and treated with 250 μM H2O2 for 5 min (A–D). After treatments, cells were fixed, permeabilized and stained for F-actin and paxillin as in Figure 3. In E, exponentially growing HUVECs were pretreated with vehicle (0.25% DMSO, 60 min) or with MLCK inhibitor ML-7 (25 μM, 60 min) and treated or not with 250 μM H2O2 for 30 min. After treatments, cells were processed as in A–D. Blebbing cells were counted, as in Figure 1, and mean from three separate experiments was calculated. (F) Exponentially growing HUVECs were labeled with H3[32P]O4 and were pretreated simultaneously with the phosphatase inhibitor NaF (1 mM) and with vehicle (0.25% DMSO, 60 min; lanes 1 and 2), or with ML-7 (25 μM, 60 min; lanes 3 and 4) before being treated or not (lanes 1 and 4) for 30 min with 250 μM H2O2 (lanes 2 and 3). Proteins were extracted, immunoprecipitated using anti-tropomyosin antibody, and antigen–antibody complexes were run into 8.5% SDS-PAGE. Representative autoradiogram from two separate experiments is shown. (G) Exponentially growing HUVECs were pretreated with vehicle (0.25% DMSO, 60 min; lanes 1 and 2), or with ML-7 (25 μM, 60 min; lanes 3 and 5), or with PD098059 (50 μM, 60 min; lane 4) before being treated or not (lanes 1 and 5) for 5 min with 250 μM H2O2 (lanes 2, 3, and 4). Proteins were extracted, were run into 10% SDS-PAGE, and transferred on nitrocellulose membrane. Immunodectections with mouse monoclonal anti-phospho-ERK antibody (top) and rabbit polyclonal anti-ERK antibody (bottom) are shown.